Immunotherapy Treatment Improves PFS in Advanced Triple-Negative Breast Cancer
Atezolizumab (Tecentriq) plus chemotherapy nab-paclitaxel (Abraxane) significantly reduced the risk of disease worsening or death in patients with metastatic triple-negative breast cancer.
Atezolizumab (Tecentriq) plus chemotherapy nab-paclitaxel (Abraxane) significantly reduced the risk of disease worsening or death in patients with metastatic triple-negative breast cancer, according to a Roche press release.
According to results from the phase 3 IMpassion130 study, the combination therapy met its co-primary endpoint of progression-free survival (PFS).
Atezolizumab is a monoclonal antibody designed to bind with the PD-L1 protein, blocking its interactions with both PD-1 and B7.1 receptors. The drug is already FDA-approved for the patients with previously treated metastatic non-small cell lung cancer and for certain types of metastatic urothelial carcinoma.
In the trial, PFS was met in the intention-to-treat and PD-L1 positive population with metastatic or unresectable locally advanced triple-negative breast cancer, an aggressive disease for which there are limited treatment options. Additionally, overall survival (OS) results at interim analysis in the PD-L1 population were encouraging.
Click to continue reading on Specialty Pharmacy Times.